###begin article-title 0
###xml 65 75 65 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3
###end article-title 0
###begin p 1
Present address: Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.
###end p 1
###begin p 2
###xml 467 477 467 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 808 815 808 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 830 837 830 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 252 267 <span type="species:ncbi:10090">transgenic mice</span>
###xml 277 284 <span type="species:ncbi:9606">patient</span>
###xml 989 997 <span type="species:ncbi:9606">patients</span>
Protein cleavage is a common feature in human neurodegenerative disease. Ataxin-3 protein with an expanded polyglutamine (polyQ) repeat causes spinocerebellar ataxia type-3 (SCA3), also called Machado-Joseph disease, and is cleaved in mammalian cells, transgenic mice and SCA3 patient brain tissue. However, the pathological significance of Ataxin-3 cleavage has not been carefully examined. To gain insight into the significance of Ataxin-3 cleavage, we developed a Drosophila SL2 cell-based model as well as transgenic fly models. Our data indicate that Ataxin-3 protein cleavage is conserved in the fly and may be caspase-dependent as reported previously. Importantly, comparison of flies expressing either wild-type or caspase-site mutant proteins indicates that Ataxin-3 cleavage enhances neuronal loss in vivo. This genetic in vivo confirmation of the pathological role of Ataxin-3 cleavage indicates that therapies targeting Ataxin-3 cleavage might slow disease progression in SCA3 patients.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 362 363 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C1">1</xref>
###xml 482 483 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C2">2</xref>
###xml 680 681 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C3">3</xref>
###xml 682 683 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C4">4</xref>
###xml 849 850 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C5">5</xref>
###xml 1009 1010 997 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C6">6</xref>
###xml 833 840 <span type="species:ncbi:9606">patient</span>
###xml 1003 1007 <span type="species:ncbi:10090">mice</span>
Protein cleavage plays a critical role in a number of different neurodegenerative disease situations. Cleavage of amyloid precursor protein (APP) by a series of proteases leads to the production of beta-amyloid (Abeta) peptide and the relative abundance of Abeta 42 versus Abeta 40 is thought to play an important role in the development of Alzheimer's disease (1). Increasing evidence also indicates that caspase-mediated cleavage of APP plays important roles in Abeta production (2). Tau protein, found in Alzheimer's disease and other disease lesions, is also subject to cleavage by caspases, which may contribute to disease progression in Alzheimer's disease and tauopathies (3,4). Huntingtin protein, which is responsible for Huntington's disease (HD), is also cleaved by proteases and its cleavage fragments are detected in HD patient brains (5). Site-directed mutagenesis targeting a caspase recognition site of the Huntingtin protein was shown to drastically reduce HD-like neurodegeneration in mice (6).
###end p 4
###begin p 5
###xml 375 380 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 402 409 402 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 946 947 946 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 948 949 948 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C8">8</xref>
###xml 1038 1039 1038 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 264 269 <span type="species:ncbi:10090">mouse</span>
###xml 292 297 <span type="species:ncbi:9606">human</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 1022 1027 <span type="species:ncbi:9606">human</span>
###xml 1028 1036 <span type="species:ncbi:9606">patients</span>
HD is one of a larger class of diseases known as polyglutamine (polyQ) diseases, of which there are numerous ataxias, including the most common dominantly inherited ataxia spinocerebellar ataxia type-3 [SCA3, also known as Machado-Joseph disease (MJD)]. Data from mouse transgenic models and human disease tissue indicate that the pathogenic Ataxin-3 protein, encoded by the ATXN3 gene, is proteolyzed in vivo (7). In mice, proteolysis is seen in transgenic lines with high protein expression levels that show degeneration, and is stronger in animals that are sick, and milder in those without symptoms. A normal protein cleavage product is reported, although it is unclear whether protein expression levels are comparable with that of disease animals. Epitope mapping of the cleavage site indicated that it occurs N-terminal to aa221, more recently narrowed to N-terminal to aa190, and the resulting cleavage fragment includes the polyQ repeat (7,8). A similar proteolytic fragment was seen in western samples from three human patients (7). These studies suggest that proteolysis of the pathogenic protein may occur, may contribute to disease, and that the stable fragment contains the pathogenic polyQ repeat.
###end p 5
###begin p 6
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
###xml 391 396 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 399 400 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 473 480 <span type="species:ncbi:9606">patient</span>
In a second study, proteolysis of the normal and pathogenic Ataxin-3 proteins was seen in Cos-7 cells upon staurosporine-induced apoptosis (9). Endogenous Ataxin-3 with a normal polyQ length repeat also underwent cleavage with staurosporine treatment. The cleavage in these situations was inhibited by caspase inhibitor zVAD-fmk. The cleavage was mapped to a similar location as in the Goti et al. (7) study, and was shown to be largely caspase-1 dependent. Examination of patient brain tissue for proteolytic fragments failed to reveal a clear fragment.
###end p 6
###begin p 7
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C10">10</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C13">13</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C14">14</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C15">15</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C16">16</xref>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C13">13</xref>
###xml 1171 1173 1171 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C17">17</xref>
###xml 29 34 <span type="species:ncbi:9606">human</span>
Drosophila models expressing human Ataxin-3 proteins have provided novel insights into SCA3 disease (10-13). The Ataxin-3 protein has an N-terminal ubiquitin protease domain, with the polyQ repeat near the C-terminal region of the protein (14). The ubiquitin protease domain has been shown to have de-ubiquitination activity, and is speculated to be a ubiquitin chain editing enzyme (15,16). In the fly, the activity of the normal protein associated with the ubiquitin protease domain substantially mitigates toxicity of the pathogenic protein (13). When this domain is deleted (as with an N-terminally truncated protein), or if the ubiquitin protease domain is mutated to make it inactive (C14A mutation), the protein with a pathogenic repeat is substantially more toxic in both degree and tissue range of toxicity. These data indicate that the N-terminal domain has activity to mitigate toxicity of the pathogenic protein, and that, should N-terminal proteolysis occur, it is predicted to substantially enhance toxicity of the protein. N-terminal truncation of the protein also affects the ability of the protein to interact with P97/VCP, which also enhances toxicity (17).
###end p 7
###begin p 8
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C18">18</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C19">19</xref>
###xml 264 271 264 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 383 390 383 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
###xml 128 135 <span type="species:ncbi:9606">patient</span>
###xml 285 294 <span type="species:ncbi:7227">fruit fly</span>
###xml 600 605 <span type="species:ncbi:9606">human</span>
Previous reports about Ataxin-3 protein cleavage are in cell-based studies or correlative studies in transgenic mouse models or patient brain samples (7,9,18,19). In order to gain experimental evidence of the pathological significance of Ataxin-3 protein cleavage in vivo, we used the fruit fly model system to define potential cleavage of the Ataxin-3 protein in the nervous system in vivo, and the consequences of preventing that cleavage pattern. Our data suggest that Ataxin-3 cleavage enhances the progression of neurodegeneration in the fly model for SCA3, indicating that such cleavage in the human situation may enhance disease progression.
###end p 8
###begin title 9
RESULTS
###end title 9
###begin title 10
###xml 31 41 31 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
Ataxin-3 protein is cleaved in Drosophila in a pattern similar to mammals
###end title 10
###begin p 11
###xml 335 336 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 337 338 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
###xml 435 445 423 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 737 738 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F1">1</xref>
###xml 742 743 730 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 744 745 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
###xml 746 748 734 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C18">18</xref>
###xml 195 200 <span type="species:ncbi:10090">mouse</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
Studies using various antibodies suggest that the major cleavage product of Ataxin-3 includes the polyQ domain, and that expanded pathogenic Ataxin-3 protein from the brain tissues of transgenic mouse models or SCA3 patients generates a approximately36 kDa fragment, with the size fragment dependent on the length of the polyQ repeat (7,9). We examined whether similar protein cleavage products were generated in the nervous system of Drosophila expressing Ataxin-3 with either normal length (Atx3Q27) or expanded polyQ domain (Atx3Q84). Polyclonal antibody to Ataxin-3 and the monoclonal antibody 1H9, which recognizes aa221-224, as well as anti-Myc and anti-Flag antibodies, were chosen to compare our data with previous studies (Fig. 1A) (7,9,18). Previously reported Myc-tagged Ataxin-3 proteins of normal or expanded polyQ length were used along with newly generated double-tagged (N-terminal Myc and C-terminal Flag) proteins.
###end p 11
###begin p 12
###xml 52 62 52 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 65 66 65 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 186 187 186 187 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 194 195 194 195 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 777 787 753 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 1265 1295 1205 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elav-gal4/+; UAS-Myc-Atx3Q27/+</italic>
###xml 1299 1316 1239 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UAS-Myc-Atx3Q84/+</italic>
###xml 1325 1360 1265 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elav-gal4/+; UAS-Myc-Atx3Q84-Flag/+</italic>
###xml 420 425 <span type="species:ncbi:10090">mouse</span>
###xml 1109 1114 <span type="species:ncbi:10090">mouse</span>
###xml 1128 1135 <span type="species:ncbi:9606">patient</span>
Ataxin-3 protein cleavage products are generated in Drosophila. (A) Schematic representation of Ataxin-3 proteins used. Site of the epitopes for the antibodies used are also indicated. (B) and (C) Western immunoblot analysis of proteins expressed in the brain of 7d fly heads. (B) Initial studies performed with Myc-Atx3Q27 and Myc-Atx3Q84 proteins. Left, Anti-Myc antibody detects the full-length proteins. Middle, the mouse monoclonal antibody 1H9 and right, the polyclonal anti-MJD antibody detect Ataxin-3 fragments migrating at approximately22 kDa for Atx3Q27 and approximately37 kDa for Atx3Q84. Each antibody also detects non-specific bands when compared with the control. Strong signals are detected as SDS-insoluble fractions in the stacking gel. (C) Left, transgenic Drosophila head extracts expressing Myc-Atx3Q84-Flag show a similar cleavage pattern by 1H9, of the full-length protein and approximately37 kDa fragments. Right, anti-Flag antibody detects the full-length protein and a approximately37 kDa fragment. These data suggest that approximately37 kDa fragments, also reported in transgenic mouse and some MJD patient samples, are likely to contain the C-terminal portion of MJD protein, as well as the polyQ domain of the protein. Genotypes: (B) elav-gal4/+; UAS-Myc-Atx3Q27/+ or UAS-Myc-Atx3Q84/+ and (C) elav-gal4/+; UAS-Myc-Atx3Q84-Flag/+. Full-length proteins, <Q84 or <Q27, fragments indicated as *Q27f and *Q84f.
###end p 12
###begin p 13
###xml 171 178 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F1">1</xref>
###xml 735 736 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F1">1</xref>
###xml 844 845 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 935 945 887 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 1267 1268 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C1">1</xref>
###xml 1338 1345 1290 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 827 832 <span type="species:ncbi:10090">mouse</span>
###xml 837 842 <span type="species:ncbi:9606">human</span>
Analysis of the cleavage patterns of the normal and pathogenic protein with these different antibodies revealed that the Ataxin-3 protein is cleaved in the nervous system in vivo to generate smaller stable fragments that include the polyQ repeat (Fig. 1B). With the 1H9 and anti-MJD antibodies, significant amounts of cleavage products were readily detected. The pathogenic Atx3Q84 protein runs at approximately73 kDa, and is cleaved to generate fragments running at approximately37 kDa. Depending on the antibody, the cleavage product appears as a doublet or single band. The normal length Atx3Q27 protein generates a smaller fragment of approximately22 kDa, suggesting that the major cleavage product includes the polyQ domain (Fig. 1B). The presence of approximately37 kDa fragments, similar in size to the fragment seen in mouse and human (7), with expression of pathogenic Ataxin-3 suggests that Ataxin-3 cleavage is conserved in Drosophila. Interestingly, our initial studies showed that cleavage of Ataxin-3 was much more prominent when the protein was expressed in the nervous system than in the eye, which has predominantly accessory cells along with neuronal cells (). The full-length Ataxin-3 protein is also not very toxic to non-neural cells of the eye (1), suggesting that the cleavage of the protein may be more particular in vivo to the nervous system, and that this may relate to the toxicity of the protein.
###end p 13
###begin p 14
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F1">1</xref>
###xml 654 655 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F1">1</xref>
The anti-Myc antibody which recognizes the N-terminal end of tagged forms of Ataxin-3 protein highlighted the full-length protein, which migrated just below the 75 kDa marker, and no significant smaller products (Fig. 1B). This indicated that cleavage products do not include the N-terminal end of the protein. With the double-tagged protein, we observed a similar cleavage pattern of the Atx3Q84 protein indicating C-terminal cleavage. Notably, antibodies to the C-terminal FLAG tag detect a cleavage product migrating just above approximately37 kDa, further confirming that stable cleavage products are derived from the C-terminus of the protein (Fig. 1C).
###end p 14
###begin title 15
Caspase inhibitor zVAD-fmk inhibits Ataxin-3 protein cleavage in S2 cells
###end title 15
###begin p 16
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C19">19</xref>
###xml 210 218 210 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C18">18</xref>
###xml 363 373 363 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F2">2</xref>
Previous reports suggest that Ataxin-3 protein cleavage is dependent on caspase activities and is blocked by caspase inhibitors (9,19). Calpain proteases and the proteasome have also been implicated in studies in vitro using neuroblastoma cell extracts (18). To further define potential proteases that may function for protein cleavage in the fly, we developed a Drosophila SL2 cell-based system to determine whether the Ataxin-3 protein is proteolyzed by any of the proteases previously implicated using various chemical inhibitors (Fig. 2A).
###end p 16
###begin p 17
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 304 312 304 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pHS-gal4</italic>
###xml 356 373 356 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pUAST-Myc-Atx3Q84</italic>
###xml 490 491 490 491 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 723 730 699 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 582 588 <span type="species:ncbi:4039">carrot</span>
zVAD, a broad-acting caspase inhibitor, can suppress Ataxin-3 protein cleavage in an SL2-cell-based system. (A) Experimental procedure to detect the effect of various protease inhibitors on Ataxin-3 protein cleavage in SL2 cells. Expression of the Ataxin-3 protein was driven by heat shock using a Gal4 (pHS-gal4) construct. The construct in all cases was pUAST-Myc-Atx3Q84. Drug was added 1 h prior to the first heat shock and was then continuously present until harvesting of the cells. (B) Ataxin-3 protein cleavage pattern in SL2 cells. The full-length protein is marked with a carrot (<) and the approximately37 kDa fragments highlighted with an arrow. In addition to the approximately37 kDa fragments seen in the fly in vivo, additional Ataxin-3 fragments were detected in SL2 cells, most prominently a fragments at approximately50 kDa (*). zVAD, a general caspase inhibitor, inhibited the production of the approximately37 kDa fragments, without significantly altering the generation of the approximately50 kDa fragment. zFA, a control peptide, had no effect. All drugs were dissolved in DMSO, with final percentage of DMSO indicated.
###end p 17
###begin p 18
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 167 168 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F2">2</xref>
###xml 283 290 271 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 424 425 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F2">2</xref>
###xml 656 657 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F2">2</xref>
As observed in the fly in vivo, we detected the approximately37 kDa cleavage products when the pathogenic Atx3Q84 protein was transiently expressed in SL2 cells (Fig. 2B). The cleavage pattern of the protein in SL2 cells was similar to the cleavage pattern of the protein in the fly in vivo (). Additional cleavage products were also detected in cultured cells, most prominently a fragment of approximately50 KDa (* in Fig. 2B, ** in ). We then used inhibitors to define potential cleaving proteases. zVAD-fmk, a broad caspase inhibitor, consistently reduced the level of approximately37 kDa fragment, while the control peptide zFA-fmk had no effect (Fig. 2B,  and ). Interestingly, with zVAD-fmk, there appeared to be an accumulation of a higher molecular weight fragment (**in ), suggesting the possibility of sequential processing of the Ataxin-3 protein.
###end p 18
###begin p 19
###xml 128 136 128 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C18">18</xref>
Although the proteasome inhibitor MG-132 and the calpain inhibitor ALLN have been previously shown to inhibit Ataxin-3 cleavage in vitro (18), in SL2 cells, only MG-132 inhibited the appearance of a minor band (*** in ), but it did not inhibit generation of the approximately37 kDa fragments. Furthermore, when zVAD-fmk and MG-132 were combined, the results were additive rather than synergistic, suggesting that the proteasome and caspases may act independently.
###end p 19
###begin title 20
Site-directed mutagenesis of caspase-recognition sites significantly modify Ataxin-3 protein cleavage in cells and in the fly
###end title 20
###begin p 21
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 13 14 13 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
###xml 566 576 566 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 869 870 857 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F3">3</xref>
Goti et al. (7) used a series of monoclonal antibodies to identify the potential Ataxin-3 protein cleavage site. Those studies indicated that the cleavage site may be near or just anterior to the ubiquitin-interacting motifs (UIMs) N-terminal to the polyQ repeat. Berke et al. (9) reported several putative caspase-recognition sites and showed that the modification of six or nine caspase sites by site-directed mutagenesis eliminated the appearance of cleavage products in Cos-7 cells. The data with zVAD-fmk indicated that Ataxin-3 is a target of caspases also in Drosophila cells. To test the significance of caspase cleavage, we modified the aspartic acid residues to asparagines at select caspase sites. Because of our interest in the approximately37 kDa fragments, we focused on the six putative caspase sites at amino acids 171, 208, 217, 223, 225 and 228 (Fig. 3A).
###end p 21
###begin p 22
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 121 122 121 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 262 263 262 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 693 718 669 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elav-gal4/UAS-Myc-Atx3Q84</italic>
###xml 720 756 696 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elav-gal4/ UAS-Myc-Atx3Q84-Flag (WT)</italic>
###xml 761 796 737 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elav-gal4/UAS-Myc-Atx3Q83-Flag (6M)</italic>
###xml 753 755 <span type="species:ncbi:34205">WT</span>
Mutation of putative caspase recognition sites in Ataxin-3 dramatically reduces the amount of cleavage product in vivo. (A) Schematic diagram of Atx3Q83 protein with the positions noted of the six caspase sites targeted in the site-directed mutagenesis (D->N). (B) Western immunoblots. Top panel, Ataxin-3 protein cleavage pattern probed with anti-MJD polyclonal antibody. Head extracts from 7d adult flies were used. Sextuplet mutation strongly suppresses Ataxin-3 protein cleavage. A non-specific band (*, approximately70 kDa) masks the full-length band. SDS-insoluble fractions are within the stacking gel, and the approximately37 kDa cleavage products (**U and **D) are marked. Genotypes: elav-gal4/UAS-Myc-Atx3Q84, elav-gal4/ UAS-Myc-Atx3Q84-Flag (WT) and elav-gal4/UAS-Myc-Atx3Q83-Flag (6M). Two transgenic lines of each genotype are shown. Lower panels are the same blot, probed with Anti-Myc for the full-length protein, and with Anti-tubulin, for a loading control.
###end p 22
###begin p 23
###xml 724 725 712 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
###xml 726 728 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C19">19</xref>
Upon generation of the caspase-resistant forms, we found that caspase cleavage of Ataxin-3 is a dynamic process. That is, single site (D208N or D217N) or even triple mutation (D171/208/217N) of the putative caspase sites did not fully eliminate cleavage, but rather lead to an alteration in the cleavage pattern in SL2 cells ( and data not shown). Strikingly, however, elimination of all six putative caspase-sites (6M) eliminated the approximately37 kDa fragments in SL2 cells (). Such mutation of the protein also had an effect on the overall mobility of the protein in gels. This may be due to a conformational change caused by the mutations or could result from additional cleavage at the C-terminal end of the protein (9,19).
###end p 23
###begin p 24
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 416 423 416 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F3">3</xref>
###xml 551 552 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F3">3</xref>
###xml 206 208 <span type="species:ncbi:34205">WT</span>
To extend these findings in vivo in order to understand the pathological impact of modified Ataxin-3 protein cleavage, we generated transgenic animals expressing either wild-type protein (Myc-Atx3Q84-Flag (WT)) or the sextuplet mutant protein (Myc-Atx3Q83-Flag (6M)). Analysis of flies expressing equal levels of these proteins revealed that the 6M mutant protein had dramatically reduced levels of cleavage product in vivo (Fig. 3). Whereas the Myc-Atx3-Q84 protein showed two cleavage products at the approximately37 kDa region (**U and **D in Fig. 3B), the upper fragment of the double-tagged Myc-SCA3Q84-Flag protein was typically more prominent; thus, the C-terminal Flag tag may influence the Ataxin-3 protein cleavage process. The 6M mutant protein, however, which also contained the C-terminal Flag tag, completely lacked the upper approximately37 kDa band, and only faint signals were detected for the lower molecular weight fragment.
###end p 24
###begin p 25
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F3">3</xref>
The amount of SDS-insoluble material in the stacking gel in the 6M caspase-mutant form of the protein was also significantly reduced, as detected by the anti-MJD antibody (Fig. 3B). Interestingly, the amount of SDS-insoluble material trapped in the stacking gel appeared to correlate with the amount of the upper approximately37 kDa product (**U). In the 6M transgenic lines, lines with the lowest amount of cleavage product also showed the lowest amount of SDS-insoluble material with the anti-MJD antibody (data not shown).
###end p 25
###begin title 26
Sextuplet caspase-site mutation (6M) does not significantly modify nuclear inclusion formation
###end title 26
###begin p 27
###xml 471 478 459 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 514 522 502 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rh1-Gal4</italic>
###xml 586 588 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C11">11</xref>
###xml 589 591 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C13">13</xref>
The correlation between the amount of SDS-insoluble material by western analysis and the amount of the upper approximately37 kDa fragment raised the interesting hypothesis that this fragment may act as a seed for the formation of nuclear inclusions in tissues expressing the pathogenic Ataxin-3 protein. To test this hypothesis, we conducted a time course experiment to determine whether there was a difference in onset or size of nuclear inclusion formation by Ataxin-3 in vivo. We used the late-onset rhodopsin (rh1-Gal4) driver that allows sensitive analysis of inclusion formation (11,13).
###end p 27
###begin p 28
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F4">4</xref>
###xml 73 75 <span type="species:ncbi:34205">WT</span>
###xml 191 193 <span type="species:ncbi:34205">WT</span>
###xml 321 323 <span type="species:ncbi:34205">WT</span>
These studies revealed no difference in protein accumulation between the WT and 6M form of pathogenic Ataxin-3 with 7d animals, showing a similar level and size of nuclear inclusions between WT and 6M flies (Fig. 4). Analysis at earlier time points also indicated that the rate of inclusion formation was similar between WT and 6M flies (data not shown). Therefore, mutation of the caspase cleavage sites and reduced proteolysis of the pathogenic Ataxin-3 protein does not affect protein accumulation. This finding also suggests that protein misfolding and clearance are not significantly affected by the presence of these caspase cleavage products, in agreement with MG-132 data from SL2 cells (see ).
###end p 28
###begin p 29
###xml 329 337 329 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rh1-gal4</italic>
###xml 740 775 740 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rh1-gal4/ UAS-Myc-Atx3Q84-Flag (WT)</italic>
###xml 780 815 780 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rh1-gal4/ UAS-Myc-Atx3Q83-Flag (6M)</italic>
###xml 457 459 <span type="species:ncbi:34205">WT</span>
###xml 772 774 <span type="species:ncbi:34205">WT</span>
Elimination of putative caspase cleavage sites in Ataxin-3 protein has little impact on protein accumulations. Cryosections immunostained for Ataxin-3 protein with Myc (green, left panels) and for nuclei with Hoechst (blue, right panels) of retinal sections from 7d adult flies. Protein was expressed with an adult onset driver (rh1-gal4), which is a sensitive method to detect subtle differences in nuclear inclusion formation. Flies expressing either the WT protein (top) or the 6M protein (bottom) showed inclusions typical of the full-length Ataxin-3 protein, being of irregular shape when assayed with this late-onset driver, and had the same onset and size. Higher magnification insets are also included in the Myc panels. Genotypes: rh1-gal4/ UAS-Myc-Atx3Q84-Flag (WT) and rh1-gal4/ UAS-Myc-Atx3Q83-Flag (6M).
###end p 29
###begin title 30
Sextuplet caspase site mutation mitigates neurodegeneration
###end title 30
###begin p 31
###xml 199 208 199 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elav-gal4</italic>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F5">5</xref>
###xml 1121 1122 1117 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP456F5">5</xref>
###xml 1125 1127 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C13">13</xref>
###xml 139 141 <span type="species:ncbi:34205">WT</span>
###xml 343 345 <span type="species:ncbi:34205">WT</span>
###xml 455 457 <span type="species:ncbi:34205">WT</span>
We next asked whether reduction in caspase cleavage modulates Ataxin-3 protein toxicity. Transgenic lines expressing the same level of the WT or 6M proteins were expressed in the nervous system with elav-gal4, and photoreceptor degeneration was assessed. Animals at 1d showed a mild degeneration that was similar with expression of either the WT or 6M protein, with 6-7 photoreceptor neurons per unit eye ommatidial cluster (Fig. 5). Flies expressing the WT pathogenic protein, however, then underwent rapid neural loss, such that 15d animals retained only 3.1 +/- 0.34 photoreceptor neurons per ommatidial cluster. In contrast, 15d flies expressing the 6M caspase mutant protein had strikingly less degeneration, with 5.19 +/- 0.17 PR neurons per ommatidial unit remaining. To confirm that the 6M mutant protein was properly folded despite the caspase site mutations, we tested whether the ability to suppress the pathogenicity of the truncated SCA3Q78 protein was retained. Normally, the pathogenic full-length Ataxin-3 protein, when co-expressed with the truncated Q78 protein, has activity to suppress toxicity (Fig. 5C; 13). These studies showed that the 6M protein retained suppressor activity comparable with that of the protein without caspase site mutations; this indicates that the 6M protein retains normal Ataxin-3 activity and thus is likely properly folded. Taken together, these data indicate that blocking caspase cleavage of the Ataxin-3 protein dramatically mitigates neural toxicity, despite the fact that nuclear inclusion formation is unaffected.
###end p 31
###begin p 32
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 270 271 270 271 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 633 673 631 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elav-gal4/+; UAS-Myc-Atx3Q84-Flag (WT)/+</italic>
###xml 682 723 680 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elav-gal4/+; pUAS-Myc-Atx3Q83-Flag (6M)/+</italic>
###xml 726 727 724 725 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1111 1113 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C13">13</xref>
###xml 1473 1665 1471 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gmr-gal4 UAS-SCA3trQ78(S)/+. gmr-gal4 UAS-SCA3trQ78(S)/UAS-Myc-Atx3Q27-Flag [WT(Q27)]. gmr-gal4 UAS-SCA3trQ78(S)/UAS-Myc-Atx3Q84-Flag (WT). gmr-gal4 UAS-SCA3trQ78(S)/ UAS-Myc-Atx3Q83-Flag (6M)</italic>
###xml 238 240 <span type="species:ncbi:34205">WT</span>
###xml 331 333 <span type="species:ncbi:34205">WT</span>
###xml 586 588 <span type="species:ncbi:34205">WT</span>
###xml 629 631 <span type="species:ncbi:34205">WT</span>
###xml 668 670 <span type="species:ncbi:34205">WT</span>
###xml 976 978 <span type="species:ncbi:34205">WT</span>
###xml 1140 1142 <span type="species:ncbi:34205">WT</span>
###xml 1291 1293 <span type="species:ncbi:34205">WT</span>
###xml 1550 1552 <span type="species:ncbi:34205">WT</span>
###xml 1608 1610 <span type="species:ncbi:34205">WT</span>
Suppression of Ataxin-3 protein cleavage slows down the progression of photoreceptor neuronal degeneration. (A) Images of the retina by pseudopupil technique, showing 1d and 15d representative images of flies expressing Myc-Atx3Q84-Flag (WT) and Myc-Atx3Q83-Flag (6M). (B) Quantitation of the number of photoreceptor neurons in 1d WT (green) and 6M (red) flies. At 1d, flies of both genotypes showed a similar degree of mild photoreceptor neuron degeneration. Average number of photoreceptor neurons indicated +/- SD. 15d adult animals show greater degeneration in flies expressing the WT protein than the 6M protein. Genotypes: WT, elav-gal4/+; UAS-Myc-Atx3Q84-Flag (WT)/+ and 6M, elav-gal4/+; pUAS-Myc-Atx3Q83-Flag (6M)/+. (C) The 6M protein retains normal Ataxin-3 activity to suppress pathogenicity of the truncated Q78 protein. External eye pictures. Flies expressing the truncated Q78 protein alone (-) have a degenerate eye. The normal non-pathogenic Ataxin-3 protein [WT(Q27)] suppresses this toxicity when co-expressed; this suppression reflects the normal functional activity of the Ataxin-3 protein (13). The pathogenic protein (WT) also shows suppressor activity, although not as striking as the non-pathogenic protein. The 6M protein (6M) has suppressor activity similar to the WT pathogenic protein. This indicates that the 6M protein is likely properly folded because it retains normal activity of the Ataxin-3 protein to suppress polyQ toxicity. Genotypes: gmr-gal4 UAS-SCA3trQ78(S)/+. gmr-gal4 UAS-SCA3trQ78(S)/UAS-Myc-Atx3Q27-Flag [WT(Q27)]. gmr-gal4 UAS-SCA3trQ78(S)/UAS-Myc-Atx3Q84-Flag (WT). gmr-gal4 UAS-SCA3trQ78(S)/ UAS-Myc-Atx3Q83-Flag (6M).
###end p 32
###begin title 33
DISCUSSION
###end title 33
###begin p 34
###xml 86 93 86 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 285 292 285 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 360 367 360 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Here we show that the Ataxin-3 protein undergoes cleavage in SL2 cells and in the fly in vivo. Cleavage of the protein has been suggested to be important in the disease process (7). We also show that mutation of six caspase sites in the protein, which prevents cleavage of the protein in vivo, dramatically mitigates neural degeneration. These studies provide in vivo evidence that cleavage of the Ataxin-3 protein in the nervous system may occur and may contribute to disease progression.
###end p 34
###begin title 35
Ataxin-3 protein cleavage is conserved
###end title 35
###begin p 36
###xml 88 98 88 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C7">7</xref>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
###xml 636 637 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
###xml 708 718 696 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 180 195 <span type="species:ncbi:10090">transgenic mice</span>
###xml 205 212 <span type="species:ncbi:9606">patient</span>
Ataxin-3 protein cleavage appears to be conserved as we observed cleavage products from Drosophila SL2 cells and the fly nervous system similar to those reported from Cos-7 cells, transgenic mice and SCA3 patient brain tissue (7,9). Western blot analysis, using polyclonal antibodies and the 1H9 antibody, indicates that the major cleavage product from transgenic flies contains the polyQ domain, because the size of cleavage fragment varied depending upon the polyQ length. Moreover, the approximately37 kDa fragments were greatly reduced upon zVAD-fmk treatment that inhibits caspase activity, similar to the findings in Cos-7 cells (9). Overall conservation of the Ataxin-3 cleavage pattern suggests that Drosophila can be used as a model to study the mechanism and significance of the protein cleavage.
###end p 36
###begin p 37
###xml 368 373 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C19">19</xref>
One hypothesis we had initially was that Ataxin-3 cleavage fragments may act as seeds or facilitators of protein aggregation. According to that hypothesis, we expected to see a delay in nuclear inclusion formation or reduced inclusions in flies expressing the 6M mutant protein. However, there was no obvious difference in inclusion onset, size or accumulation. Pozzi et al. (19) identified multiple Ataxin-3 protein cleavage products in Cos-7 cells and concluded that polyQ expansion in the Ataxin-3 protein partially inhibited its proteolysis. Additionally, it was suggested that the reduced proteolytic degradation may enhance accumulation of full-length Ataxin-3 protein, and thereby contribute to disease. Our data showed no obvious difference in the dynamics of protein accumulation with or without Ataxin-3 cleavage, and suggested that the ubiquitin proteasome system is not differentially affected by caspase site mutations. Despite this, we did see a significant reduction in the rate of photoreceptor neural degeneration when Ataxin-3 protein cleavage was inhibited by mutation.
###end p 37
###begin p 38
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C13">13</xref>
###xml 401 408 401 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C13">13</xref>
###xml 746 752 746 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
The UIM domains have been found to modulate toxicity of the pathogenic Ataxin-3 protein (13). Because the 6M mutations potentially affect residues in the first UIM domain, it is possible that the resulting changes in UIM function may change the overall toxicity. However, loss of UIM function has been shown to increase, rather than decrease, Ataxin-3 toxicity as observed here. We also used an assay in vivo, the ability to suppress polyQ toxicity, to assess Ataxin-3 function of the 6M mutant protein (13). This showed that the 6M protein retains normal Ataxin-3 activity. Thus, we suggest that the 6M mutant protein shows reduced toxicity as a result of reduced protein cleavage. Overall, these observations indicate that the cleavage product per se may contribute to disease progression.
###end p 38
###begin title 39
Protein cleavage and neurodegeneration
###end title 39
###begin p 40
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C20">20</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C21">21</xref>
###xml 439 441 <span type="species:ncbi:34205">WT</span>
Cleavage of the protein may enhance neurodegeneration in vivo in multiple ways. Cleavage fragments containing the polyQ domain may interact with other proteins in a more robust manner. Nuclear inclusions in polyQ diseases may have components with differing exchange rates (20), and the presence of short cleavage products may be more potent in sequestering key cellular factors (21). Proteomic studies may help reveal insight into why the WT protein is more toxic than the 6M protein.
###end p 40
###begin p 41
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 13 15 13 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C22">22</xref>
###xml 647 654 635 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1053 1063 1041 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 1065 1067 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C23">23</xref>
###xml 1292 1294 1280 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C24">24</xref>
Cong et al. (22) made an interesting observation that the short N-terminal fragment of Huntingtin with the expanded polyQ remained predominantly monomeric in cells. Considering the apparent lack of a gross difference in the formation of nuclear inclusions by Ataxin-3 cleavage in fly neurons, it is possible that approximately37 kDa cleavage products may not be readily recruited into macroscopic inclusions, but rather may exert toxic effects as soluble monomers. The apparent increase in the SDS-insoluble aggregates with normal Ataxin-3 protein cleavage, however, also suggests that the cleavage product may be a part of the nuclear inclusions in vivo. Moreover, the apparent decrease in the SDS-insoluble aggregates with cleavage-site mutant protein suggests that cleavage products may alter or trigger changes in the biochemical properties of Ataxin-3 accumulations. One such candidate process is cross linking by transglutaminase. A recent study using chemical inhibitors of transglutaminase showed mitigated SCA3-like disease effects when fed to Drosophila (23). While the mechanism of transglutaminase activation in the nervous system remains to be fully elucidated, Ataxin-3 cleavage fragment might selectively interact with transglutaminase and trigger cross linking of aggregates (24).
###end p 41
###begin p 42
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C16">16</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C19">19</xref>
Ataxin-3 has a ubiquitin chain-modifying activity, and especially targets Lys63 linkages in mixed linkage ubiquitin chains (16). Lys63-linked ubiquitin chains are thought to play critical roles in the NF-kB signal transduction pathway as well as in DNA repair. While the cellular targets are unknown, it is possible that cleavage of the N-terminal ubiquitin protease domain may compromise key cellular pathways normally regulated by Ataxin-3. Moreover, because the cleavage product is likely to keep the UIM domain (19), it is an interesting possibility that it may act as a dominant-negative protein in the affected pathway.
###end p 42
###begin title 43
Proteases involved in cleavage of Ataxin-3
###end title 43
###begin p 44
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C9">9</xref>
Our data indicate that caspases may be responsible for Ataxin-3 cleavage. Activation of caspases as diseased cells undergo apoptosis pathways may trigger cleavage, as is the case with endogenous Ataxin-3 protein in Cos-7 cells (9). While it is reasonable to hypothesize that expanded Ataxin-3 protein may activate caspases that proteolyze Ataxin-3, the observation that normal Ataxin-3, which does not cause neurodegeneration, is also cleaved, suggests that cleavage is not necessarily a consequence of apoptosis. Caspases have been known to play important roles in cell proliferation and differentiation, beyond their roles as inducers/executioners of apoptosis.
###end p 44
###begin p 45
###xml 216 218 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C25">25</xref>
###xml 309 316 285 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 481 486 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 489 491 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C18">18</xref>
###xml 839 847 791 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 849 851 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C18">18</xref>
In SL2 cells, there were additional fragments beyond the approximately37 kDa fragment seen in mammalian models or fly brain, suggesting that Ataxin-3 protein cleavage may be a multi-step process like for Huntingtin (25). The approximately37 kDa fragments may have the longest half-life and thereby accumulate in vivo. Furthermore, z-VAD-fmk treatment eliminated the approximately37 kDa fragment selectively in SL2 cell, leaving the approximately50 kDa fragments unaffected. Haacke et al. (18) suggested potential involvement of calpain proteases, but calpain inhibitor ALLN had no effect in Ataxin-3 cleavage in SL2 cells. The apparent discrepancy could be due to the use of different cell lines or culture conditions. MG-132 is widely used as an inhibitor of proteasome function and it was effective in reducing Ataxin-3 protein cleavage in vitro (18). We also observed that MG-132 treatment consistently reduced the appearance of some cleavage products in SL2 cells, but the approximately37 KDa fragments were not affected. When cells were treated with a combination of zVAD-fmk and MG-132, we observed an additive but not synergistic effect. These data suggest that Ataxin-3 protein cleavage is a complex process, involving multiple cellular pathways.
###end p 45
###begin p 46
###xml 96 103 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 409 416 409 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 497 502 497 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
In an attempt to define a specific caspase responsible for the cleavage of the Ataxin-3 protein in vivo, we utilized dsRNA-mediated RNA knockdown in SL2 cells and in the fly. We effectively decreased the levels of Dronc, Strica and Drice in SL2 cells, but this had no effect on the Ataxin-3 cleavage pattern (J. Jung and N. Bonini, unpublished data). We further examined knockdown of caspase genes in the fly in vivo using P35 or dsRNA transgenic lines, but no consistent effect was seen (J. Jung et al., unpublished data). It may be necessary to knock down multiple caspases at once, or knock down the genes to a greater extent than was achieved.
###end p 46
###begin p 47
###xml 57 67 57 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Our data demonstrate that Ataxin-3 protein is cleaved in Drosophila as reported in mammalian model systems and in SCA3 patients. Additionally, we provide experimental evidence that Ataxin-3 cleavage significantly enhances neural degeneration induced by the pathogenic Ataxin-3 protein. Taken together, these data indicate that suppression of Ataxin-3 protein cleavage may significantly slow down the progression of neurodegeneration caused by expanded Ataxin-3 protein expression.
###end p 47
###begin title 48
MATERIALS AND METHODS
###end title 48
###begin title 49
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
Drosophila lines
###end title 49
###begin p 50
###xml 20 29 20 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elav-gal4</italic>
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C155</italic>
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rh1-gal4</italic>
###xml 127 135 127 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gmr-gal4</italic>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C13">13</xref>
###xml 300 302 <span type="species:ncbi:34205">WT</span>
###xml 441 444 <span type="species:ncbi:9685">Cat</span>
###xml 615 617 <span type="species:ncbi:34205">WT</span>
###xml 866 868 <span type="species:ncbi:34205">WT</span>
Fly lines used were elav-gal4 (C155) for neural and brain expression, rh1-gal4 for photoreceptor cell-specific expression, and gmr-gal4 for eye expression. The Myc-tagged Ataxin-3 lines have been described (13). Constructs with Flag tags were generated by PCR and sequenced to confirm integrity. The WT double-tagged protein had a polyQ length of Q84. The putative caspase site mutant constructs were generated by site-directed mutagenesis (Cat No 12397-014, Invitrogen). Several transgenic lines were chosen and used for analysis. The polyQ length of the 6M mutant line was Q83. Typically, lines Myc-Atx3Q84-Flag (WT) line #7 and Myc-Atx3Q83-Flag (6M) line #1.1 were chosen for more detailed analysis based on western immunoblot analysis of similar protein expression with anti-Myc antibody. We also analyzed additional lines with similar results, including lines (WT) line #2 and (6M) line #3.1.
###end p 50
###begin title 51
Immunoblots and immunohistochemistry
###end title 51
###begin p 52
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C26">26</xref>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C27">27</xref>
###xml 629 631 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP456C12">12</xref>
###xml 94 100 <span type="species:ncbi:9986">Rabbit</span>
###xml 270 275 <span type="species:ncbi:10090">Mouse</span>
###xml 382 387 <span type="species:ncbi:10090">Mouse</span>
###xml 449 454 <span type="species:ncbi:10090">Mouse</span>
###xml 644 649 <span type="species:ncbi:10090">mouse</span>
###xml 739 742 <span type="species:ncbi:9685">Cat</span>
Western immunoblot analysis was performed as described (26). Antibodies used were as follows. Rabbit anti-MJD polyclonal antibody (gift of R. Pittman) (27), at 1:20 000, pre-adsorbed overnight at 4degreesC at 1:50 against 20-50 paraformaldehyde fixed, dissected larvae. Mouse monoclonal antibody 1H9 at 1:1000 (ab78546, Abcam). Anti-Flag antibody (F3165, Sigma, Company) at 1:1000. Mouse anti-Myc antibody (9E11, Santa Cruz Biotechnology) at 1:250. Mouse monoclonal anti-tubulin at 1:1000 (Developmental Studies Hybridoma Bank) was used as a loading control. Immunostaining of cryosections was performed as described previously (12), using the mouse anti-Myc antibody at 1:100. When appropriate, blots were stripped with Reblottrade mark (Cat No 2060, Millipore).
###end p 52
###begin title 53
Cell culture studies
###end title 53
###begin p 54
###xml 4 26 4 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pUAST-Myc-Atx3Q84-Flag</italic>
###xml 84 92 80 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pHS-gal4</italic>
###xml 350 360 336 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 1094 1095 1062 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 1189 1190 1157 1158 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 1259 1260 1227 1228 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 1268 1269 1236 1237 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 1277 1278 1245 1246 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 1318 1319 1286 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 165 168 <span type="species:ncbi:9685">Cat</span>
###xml 369 372 <span type="species:ncbi:9685">Cat</span>
###xml 1350 1353 <span type="species:ncbi:9685">Cat</span>
The pUAST-Myc-Atx3Q84-Flag expression vector (2 microg) was co-transfected with the pHS-gal4 driver construct (1 microg) into SL2 cells using the Effectene reagent (Cat No 11668027, Invitrogen) following the manufacturer's protocol. Transfected cells were incubated for 2 days at 25degreesC. Cells were then rinsed with PBS and fed fresh Schneider's Drosophila medium (Cat No 11720-034, Invitrogen) followed by a 30 min heat-shock treatment at 37degreesC to induce Atx3Q84 protein expression. Heat-shocked cells were cooled at 25degreesC for 30 min and the heat-shock treatment was repeated. This double heat-shock treatment was repeated twice more, with a 24 h interval in-between. Cells were harvested for analysis after 2 additional days of incubation at 25degreesC. For drug treatments, respective drug compounds were solubilized in DMSO, and then diluted to indicated concentrations in the normal growth medium. One hour prior to the first heat-shock treatment, cells were rinsed once with PBS and fed drug-containing medium, followed by the standard heat-shock treatment. Drugs used were N-benzyloxycarbonyl-val-ala-asp(O-Me) fluoromethyl ketone (zVAD-fmk, Sigma), benzyloxicarbonyl-l-phenylalanyl-ala-fluoromethylketone (Z-FA.FMK, Sigma), Carbobenzoxy-l-leucyl-l-leucyl-l-leucinal (MG-132, EMD Biosciences) and N-acetyl-Leu-Leu-Nle-CHO (ALLN, Cat No 208719, Calbiochem). Cells were kept in drug-containing medium until harvest.
###end p 54
###begin title 55
SUPPLEMENTARY MATERIAL
###end title 55
###begin p 56
.
###end p 56
###begin title 57
FUNDING
###end title 57
###begin p 58
###xml 25 111 25 111 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Institutes of Health, National Institutes of Neurological Diseases and Stroke</funding-source>
This study was funded by National Institutes of Health, National Institutes of Neurological Diseases and Stroke (to N.M.B.). N.M.B. is an Investigator of the Howard Hughes Medical Institute. Funding to pay the Open Access publication charges for this article was provided by the Howard Hughes Medical Institute.
###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin title 60
[Supplementary Data]
###end title 60
###begin title 61
ACKNOWLEDGEMENTS
###end title 61
###begin p 62
We thank Zhenming Yu for critical comments.
###end p 62
###begin p 63
###xml 0 31 0 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement.</italic>
Conflict of Interest statement. None declared.
###end p 63
###begin title 64
REFERENCES
###end title 64
###begin article-title 65
Gamma-secretase modulation and its promise for Alzheimer's disease: a rationale for drug discovery
###end article-title 65
###begin article-title 66
Caspases as therapeutic targets in Alzheimer's disease: is it time to 'cut' to the chase?
###end article-title 66
###begin article-title 67
Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease
###end article-title 67
###begin article-title 68
Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology
###end article-title 68
###begin article-title 69
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers
###end article-title 69
###begin article-title 70
Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin
###end article-title 70
###begin article-title 71
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 94 109 <span type="species:ncbi:10090">transgenic mice</span>
A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration
###end article-title 71
###begin article-title 72
###xml 130 145 <span type="species:ncbi:10090">transgenic mice</span>
A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice
###end article-title 72
###begin article-title 73
Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3
###end article-title 73
###begin article-title 74
###xml 55 65 55 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
CREB-binding protein modulates repeat instability in a Drosophila model for polyQ disease
###end article-title 74
###begin article-title 75
###xml 94 104 94 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila
###end article-title 75
###begin article-title 76
###xml 56 66 56 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
RNA toxicity is a component of ataxin-3 degeneration in Drosophila
###end article-title 76
###begin article-title 77
###xml 55 65 55 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism
###end article-title 77
###begin article-title 78
The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity
###end article-title 78
###begin article-title 79
The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation
###end article-title 79
###begin article-title 80
The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains
###end article-title 80
###begin article-title 81
An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis
###end article-title 81
###begin article-title 82
Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3
###end article-title 82
###begin article-title 83
Study of subcellular localization and proteolysis of ataxin-3
###end article-title 83
###begin article-title 84
Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components
###end article-title 84
###begin article-title 85
The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
###end article-title 85
###begin article-title 86
Small N-terminal mutant huntingtin fragments, but not wild type, are mainly present in monomeric form: Implications for pathogenesis
###end article-title 86
###begin article-title 87
###xml 41 46 <span type="species:ncbi:9606">human</span>
Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries
###end article-title 87
###begin article-title 88
Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells
###end article-title 88
###begin article-title 89
Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis
###end article-title 89
###begin article-title 90
###xml 73 83 73 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 45 50 <span type="species:ncbi:4932">yeast</span>
Suppression of polyglutamine toxicity by the yeast Sup35 prion domain in Drosophila
###end article-title 90
###begin article-title 91
Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain
###end article-title 91

